Filter

Refine by Subjects

Refine by Access

Refine by Type

Refine by Date

—
  • Print
  • Save

Browse

You are looking at 351 - 400 of 1,337 items for :

  • Clinical Resources x
  • Refine by Access: All content x
Clear All
Restricted access

Eslicarbazepine Acetate Suspension 40 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

CH 1.3 Estimating Kidney Function

John E. Murphy

Chapter

Cover Clinical Pharmacokinetics Workbook

In  Clinical Pharmacokinetics Workbook

Published (Print):
01 Jan 2022
Restricted access

CH 2.3 Estimating Kidney Function

John E. Murphy

Chapter

Cover Clinical Pharmacokinetics Workbook

In  Clinical Pharmacokinetics Workbook

Published (Print):
01 Jan 2022
Restricted access

Ethacrynic Acid Solution 1 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

14 ETHOSUXIMIDE

Jacquelyn L. Bainbridge, Pei Shieen Wong, Sarah N. Rajkovic, and Grace S. Chin

Chapter

Cover Clinical Pharmacokinetics

In  Clinical Pharmacokinetics

Published (Print):
01 Jan 2022
Restricted access

Etoposide Solution 10 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access
Cover Extemporaneous Formulations

Extemporaneous Formulations

for Pediatric, Geriatric, and Special Needs Patients

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Book

Published (Print):
Jan 2022
Restricted access

Famotidine Suspension 8 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Famotidine Syrup 8 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Flecainide Acetate Suspension 20 mg/mL—Formulation 1*

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Flecainide Acetate Suspension 20 mg/mL—Formulation 2

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Fluconazole Solution 1 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Flucytosine Suspension 10 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Flucytosine Suspension 50 mg/mL*

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Fluoxetine Hydrochloride Syrup 1 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Fluoxetine Hydrochloride Syrup 2 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Furosemide Suspension 2 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Furosemide Suspension 9.6 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Gabapentin Suspension 100 mg/mL—Formulation 1

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Gabapentin Suspension 100 mg/mL—Formulation 2

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Gabapentin Suspension 50 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Ganciclovir Intravitreous Solution 20 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Free access

CH 1.1 General Pharma­cokinetic Applications

John E. Murphy

Chapter

Cover Clinical Pharmacokinetics Workbook

In  Clinical Pharmacokinetics Workbook

Published (Print):
01 Jan 2022
Restricted access

CH 2.1 General Pharmacokinetic Applications

John E. Murphy

Chapter

Cover Clinical Pharmacokinetics Workbook

In  Clinical Pharmacokinetics Workbook

Published (Print):
01 Jan 2022
Restricted access

Gentamicin Sulfate Ophthalmic Solution 13.6 mg/mL (Fortified)

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Glutamine Suspension 250 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Glycopyrrolate Suspension 0.2 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Glycopyrrolate Suspension 0.5 mg/mL—Formulation 1

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Glycopyrrolate Suspension 0.5 mg/mL—Formulation 2

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Granisetron Hydrochloride Suspension 0.05 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Granisetron Hydrochloride Syrup 0.2 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Haloperidol Suspension 0.5 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

17 Hematology: Blood Coagulation Tests

Lea E. Dela Peña

Chapter

Cover Basic Skills in Interpreting Laboratory Data

In  Basic Skills in Interpreting Laboratory Data

Published (Print):
01 Jan 2022
Restricted access

16 Hematology: Red and White Blood Cell Tests

Michael D. Katz and Timothy C. Jacisin

Chapter

Cover Basic Skills in Interpreting Laboratory Data

In  Basic Skills in Interpreting Laboratory Data

Published (Print):
01 Jan 2022
Restricted access

Hydralazine Hydrochloride Suspension 4 mg/mL*

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Hydrochlorothiazide Suspension 2 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Hydrocortisone Hemisuccinate Suspension 2 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Hydrocortisone Sodium Phosphate Suspension 2 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Hydrocortisone Suspension 1 mg/mL—Formulation 1

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Hydrocortisone Suspension 1 mg/mL—Formulation 2

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Hydrocortisone Suspension 2 mg/mL*

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Hydroxychloroquine Sulfate Suspension 25 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Hydroxyurea Syrup 100 mg/mL*

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Hypromellose Suspension 10 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Imatinib Syrup 40 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Imipramine Hydrochloride Suspension 5 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Indinavir Liquid 10 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Indomethacin Syrup 2 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

18 Infectious Diseases: Bacteria

Sharon M. Erdman, Rodrigo M. Burgos, and Keith A. Rodvold

Chapter

Cover Basic Skills in Interpreting Laboratory Data

In  Basic Skills in Interpreting Laboratory Data

Published (Print):
01 Jan 2022
Restricted access

19 Infectious Diseases: Fungi, Viruses, and Mycobacteria

Rodrigo M. Burgos, Sharon M. Erdman, and Keith A. Rodvold

Chapter

Cover Basic Skills in Interpreting Laboratory Data

In  Basic Skills in Interpreting Laboratory Data

Published (Print):
01 Jan 2022